Haemonetics Corporation (HAE) Stock Price Hits All Time High Today

April 17, 2018 - By Richard Conner

Haemonetics Corporation (NYSE:HAE) Logo

Investors sentiment decreased to 1.11 in 2017 Q4. Its down 0.17, from 1.28 in 2017Q3. It worsened, as 20 investors sold Haemonetics Corporation shares while 77 reduced holdings. 48 funds opened positions while 60 raised stakes. 50.89 million shares or 3.15% less from 52.55 million shares in 2017Q3 were reported.
554,652 were accumulated by Schwab Charles Invest Mgmt. Rhumbline Advisers accumulated 122,859 shares. Bancorp Of America De holds 0.01% of its portfolio in Haemonetics Corporation (NYSE:HAE) for 532,849 shares. Schroder Investment Mgmt holds 20,869 shares. Citigroup Incorporated accumulated 31,873 shares. Prudential owns 0.01% invested in Haemonetics Corporation (NYSE:HAE) for 149,156 shares. Proshare Advsrs Llc invested in 0% or 10,932 shares. Bogle Invest Mgmt Lp De has invested 0.92% in Haemonetics Corporation (NYSE:HAE). Beaconlight Capital Limited Liability invested in 1.97% or 92,317 shares. Menta Capital Ltd Company owns 10,025 shares. Carroll Fincl Associates reported 25 shares stake. Strs Ohio holds 0.01% or 25,700 shares. Cubist Systematic Strategies Limited Liability Corp reported 8,961 shares. Brinker Capital invested in 0.01% or 5,687 shares. Ameritas Ptnrs owns 4,419 shares.

Since January 2, 2018, it had 0 insider buys, and 3 insider sales for $484,765 activity. $448,434 worth of Haemonetics Corporation (NYSE:HAE) shares were sold by KROLL MARK W. Basil Michelle L had sold 389 shares worth $28,097.

The stock of Haemonetics Corporation (NYSE:HAE) reached all time high today, Apr, 17 and still has $77.22 target or 3.00 % above today’s $74.97 share price. This indicates more upside for the $4.01B company. This technical setup was reported by Barchart.com. If the $77.22 PT is reached, the company will be worth $120.21 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.29% or $0.22 during the last trading session, reaching $74.97. About 140,755 shares traded. Haemonetics Corporation (NYSE:HAE) has risen 82.56% since April 17, 2017 and is uptrending. It has outperformed by 71.01% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 14. They expect $0.43 EPS, up 10.26 % or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.98M for 43.59 P/E if the $0.43 EPS becomes a reality. After $0.62 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65 % negative EPS growth.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 4 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Haemonetics Corp had 9 analyst reports since November 8, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Monday, January 8 by Jefferies. The firm has “Buy” rating given on Thursday, December 21 by Jefferies. On Tuesday, January 2 the stock rating was upgraded by Raymond James to “Market Perform”. The company was upgraded on Tuesday, January 2 by Morgan Stanley. The stock has “Buy” rating by Jefferies on Wednesday, February 7. The stock of Haemonetics Corporation (NYSE:HAE) has “Buy” rating given on Wednesday, March 28 by Morgan Stanley. The firm has “Equal-Weight” rating given on Thursday, November 9 by Morgan Stanley. Craig Hallum maintained the stock with “Hold” rating in Wednesday, November 8 report. The stock has “Overweight” rating by Morgan Stanley on Wednesday, February 7.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.01 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.